Search for Clinical Trial Results

Sponsored By

Peripheral T-cell Lymphoma - 10 Studies Found

Status Study
Completed Study Name: Alemtuzumab and CHOP Chemotherapy for Aggressive Histological Peripheral T-Cell Lymphomas
Condition: Peripheral T-cell Lymphomas
Date: 2007-03-27
Interventions: Drug: Alemtuzumab (Campath-1H) The investigational drug is alemtuzumab (Campath-1H). It is a recombinant
Completed Study Name: A Phase 1 Study of SP-02L in Relapsed or Refractory Patients With Peripheral T-cell Lymphoma (PTCL)
Condition: Peripheral T-cell Lymphoma
Date: 2011-09-13
Interventions:
  • Drug: SP-02L (darinaparsin for injection)

Active, not recruiting Study Name: Phase I/II Clinical Study of Pralatrexate in Japanese Patients With Relapsed or Refractory Peripheral T-cell Lymphoma
Condition: Peripheral T-cell Lymphoma
Date: 2013-12-04
Interventions:
  • Drug: Pralatrexate injection
  • Dietary Suppl
Recruiting Study Name: A Phase 2 Study of SP-02L in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
Condition: Peripheral T-Cell Lymphoma
Date: 2015-12-25
Interventions: Drug: SP-02L (darinaparsin for injection) Darinaparsin 300 mg/m2 once daily for 5 consecutive days every
Completed Study Name: A Phase 1 Study of SP-02L in Relapsed or Refractory Patients With Peripheral T-cell Lymphoma (PTCL) in Korea
Condition: Peripheral T-cell Lymphoma
Date: 2012-09-14
Interventions:
  • Drug: SP-02L (darinaparsin for injection)

Active, not recruiting Study Name: Phase II Study of Gemcitabine+Romidepsin in the Relapsed/Refractory Peripheral T-cell Lymphoma Patients
Condition: Peripheral T-cell Lymphoma
Date: 2013-03-28
Interventions: Drug: Romidepsin, Gemcitabine Romidepsin 12 mg/m2 d.1,8, 15 for 6 cycles + Gemcitabine 800 mg/m2 d.1, 15
Completed Study Name: Safety Study to Evaluate Monoclonal Antibody KW-0761 in Subjects With Peripheral T-cell Lymphoma
Condition: Peripheral T-Cell Lymphoma
Date: 2009-04-27
Interventions: Biological: KW-0761 The starting dose will be 0.1 mg/kg administered i.v. once every week for four weeks
Completed Study Name: A Study of Escalating Doses of Romidepsin in Association With CHOP in the Treatment of Peripheral T-Cell Lymphomas
Condition: Peripheral T Cell Lymphoma
Date: 2011-01-14
Interventions: Drug: Romidepsin and CHOP Romidepsin dose administered IV at day 1 and 8 or at day 1 without day 8 in co
Recruiting Study Name: Efficacy and Safety of Romidepsin CHOP vs CHOP in Patients With Untreated Peripheral T-Cell Lymphoma
Condition: Peripheral T-cell Lymphoma
Date: 2013-01-31
Interventions:
  • Drug: Romidepsin + CHOP Ro-CHO
RECRUITING Study Name: CMOP Regimen and Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma
Condition:
Date: 2025-01-16
Interventions: Cyclophosphamide: 750 mg/m2, d1; Mitoxantrone Hydrochloride Liposome: 20 mg/m2, d1; Vincristine: 1.4 g/m2, d1 (maximum dose of 2 mg), o